Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Pittsburgh, Pennsylvania

This page shows live ClinicalTrials.gov search results for Pittsburgh, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
2462
Shown on this page
12
Current sort
Recently updated
Location scope
Pittsburgh, PA
Filters apply within this location only.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this location

These controls apply only within Pittsburgh, Pennsylvania. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 421–432 of 2,462 matching trials in Pittsburgh, PA.
Indexed local directory records.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Pittsburgh

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Stored official records

Open in full search
Active, not recruiting Not applicable Interventional

GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

NCT06827990
View directory record Official record
Conditions
Aortic Dissection
Interventions
GORE® Ascending Stent Graft (ASG device)
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 7:17 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

NCT06616194
View directory record Official record
Conditions
Migraine
Interventions
Placebo, Rimegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
27
States / cities
Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR

NCT06560684
View directory record Official record
Conditions
Tenofovir
Interventions
Oral F/TDF Pills, TFV rectal douche
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Lawrenceville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions
Pegozafermin, Placebo
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
150
States / cities
Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 4, 2026, 2:09 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb

NCT06300996
View directory record Official record
Conditions
SMA, Spinal Muscular Atrophy, Spinal Muscular Atrophy 4, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type II
Interventions
Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)
Device
Lead sponsor
Marco Capogrosso
Other
Eligibility
16 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Recruiting Phase 2 Interventional

Advancing Transplantation Outcomes in Children

NCT06055608
View directory record Official record
Conditions
Kidney Transplant
Interventions
Anti-Thymocyte Globulin (ATG), Belatacept, Mycophenolate Mofetil, Sirolimus, Tacrolimus (Group 2), Tacrolimus (Group1)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 2:02 PM EDT
Recruiting Phase 3 Interventional

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842
View directory record Official record
Conditions
Primary Biliary Cholangitis (PBC)
Interventions
Elafibranor, Matched 80 mg placebo
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 11:34 AM EST
Recruiting Not applicable Interventional

Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

NCT05987852
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Hyperbaric Oxygen Therapy, Sham Hyperbaric Air
Device · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 1:16 PM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

NCT05946213
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2041
U.S. locations
424
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 318 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 4, 2026, 1:27 AM EST
Recruiting Phase 2 Interventional

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

NCT05408845
View directory record Official record
Conditions
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
154
States / cities
Birmingham, Alabama • Duarte, California • Dublin, California + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 7:04 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

NCT05327686
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions
Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
342
States / cities
Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 5:45 PM EST
Recruiting Not applicable Interventional

Assessment of CCM in HF With Higher Ejection Fraction

NCT05064709
View directory record Official record
Conditions
Diastolic Heart Failure, Heart Failure, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
67
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 2:48 PM EDT